DE2425678A1 - Verfahren zur herstellung eines impfstoffs gegen infektioese pferdeanaemie - Google Patents
Verfahren zur herstellung eines impfstoffs gegen infektioese pferdeanaemieInfo
- Publication number
- DE2425678A1 DE2425678A1 DE19742425678 DE2425678A DE2425678A1 DE 2425678 A1 DE2425678 A1 DE 2425678A1 DE 19742425678 DE19742425678 DE 19742425678 DE 2425678 A DE2425678 A DE 2425678A DE 2425678 A1 DE2425678 A1 DE 2425678A1
- Authority
- DE
- Germany
- Prior art keywords
- horse
- horses
- vaccine
- virus
- gamma globulin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000283073 Equus caballus Species 0.000 title claims description 43
- 229960005486 vaccine Drugs 0.000 title claims description 15
- 208000015181 infectious disease Diseases 0.000 title claims description 10
- 208000007502 anemia Diseases 0.000 title claims description 6
- 230000002458 infectious effect Effects 0.000 title claims description 6
- 238000004519 manufacturing process Methods 0.000 title description 4
- 241000283086 Equidae Species 0.000 claims description 33
- 241001465754 Metazoa Species 0.000 claims description 18
- 241000700605 Viruses Species 0.000 claims description 16
- 102000004169 proteins and genes Human genes 0.000 claims description 15
- 108090000623 proteins and genes Proteins 0.000 claims description 15
- 108010074605 gamma-Globulins Proteins 0.000 claims description 14
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 8
- 239000000427 antigen Substances 0.000 claims description 8
- 102000036639 antigens Human genes 0.000 claims description 8
- 108091007433 antigens Proteins 0.000 claims description 8
- 239000000463 material Substances 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 7
- 238000002347 injection Methods 0.000 claims description 5
- 239000007924 injection Substances 0.000 claims description 5
- HJBUBXIDMQBSQW-UHFFFAOYSA-N 4-(4-diazoniophenyl)benzenediazonium Chemical compound C1=CC([N+]#N)=CC=C1C1=CC=C([N+]#N)C=C1 HJBUBXIDMQBSQW-UHFFFAOYSA-N 0.000 claims description 4
- 239000007822 coupling agent Substances 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- BOSAWIQFTJIYIS-UHFFFAOYSA-N 1,1,1-trichloro-2,2,2-trifluoroethane Chemical compound FC(F)(F)C(Cl)(Cl)Cl BOSAWIQFTJIYIS-UHFFFAOYSA-N 0.000 claims description 2
- RTTZISZSHSCFRH-UHFFFAOYSA-N 1,3-bis(isocyanatomethyl)benzene Chemical compound O=C=NCC1=CC=CC(CN=C=O)=C1 RTTZISZSHSCFRH-UHFFFAOYSA-N 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 239000007975 buffered saline Substances 0.000 claims description 2
- 239000012153 distilled water Substances 0.000 claims description 2
- 239000002244 precipitate Substances 0.000 claims description 2
- 238000003756 stirring Methods 0.000 claims description 2
- DVKJHBMWWAPEIU-UHFFFAOYSA-N toluene 2,4-diisocyanate Chemical compound CC1=CC=C(N=C=O)C=C1N=C=O DVKJHBMWWAPEIU-UHFFFAOYSA-N 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims 2
- HUWXDEQWWKGHRV-UHFFFAOYSA-N 3,3'-Dichlorobenzidine Chemical compound C1=C(Cl)C(N)=CC=C1C1=CC=C(N)C(Cl)=C1 HUWXDEQWWKGHRV-UHFFFAOYSA-N 0.000 claims 1
- 241000713730 Equine infectious anemia virus Species 0.000 claims 1
- 238000005119 centrifugation Methods 0.000 claims 1
- 238000005360 mashing Methods 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 230000001376 precipitating effect Effects 0.000 claims 1
- 239000000047 product Substances 0.000 claims 1
- 208000009724 equine infectious anemia Diseases 0.000 description 28
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 22
- 210000002966 serum Anatomy 0.000 description 16
- 238000002255 vaccination Methods 0.000 description 14
- 201000010099 disease Diseases 0.000 description 12
- 231100000636 lethal dose Toxicity 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000002489 hematologic effect Effects 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 206010037660 Pyrexia Diseases 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- -1 fluorocarbon compound Chemical class 0.000 description 3
- 238000000265 homogenisation Methods 0.000 description 3
- 230000005012 migration Effects 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- 108010032597 Cohn fraction II Proteins 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- HFACYLZERDEVSX-UHFFFAOYSA-N benzidine Chemical compound C1=CC(N)=CC=C1C1=CC=C(N)C=C1 HFACYLZERDEVSX-UHFFFAOYSA-N 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 230000007969 cellular immunity Effects 0.000 description 2
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 230000007459 negative regulation of leukocyte migration Effects 0.000 description 2
- NUIURNJTPRWVAP-UHFFFAOYSA-N 3,3'-Dimethylbenzidine Chemical compound C1=C(N)C(C)=CC(C=2C=C(C)C(N)=CC=2)=C1 NUIURNJTPRWVAP-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 241000777300 Congiopodidae Species 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000283903 Ovis aries Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000003749 cleanliness Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US435751A US3873690A (en) | 1974-01-23 | 1974-01-23 | Equine infectious anemia vaccine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE2425678A1 true DE2425678A1 (de) | 1975-07-24 |
Family
ID=23729673
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19742425678 Pending DE2425678A1 (de) | 1974-01-23 | 1974-05-28 | Verfahren zur herstellung eines impfstoffs gegen infektioese pferdeanaemie |
Country Status (5)
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2949031A1 (de) * | 1978-12-15 | 1980-07-17 | Sandoz Ag | Vakzine |
| US5112756A (en) * | 1986-06-02 | 1992-05-12 | Canadian Patents And Development Limited | Continuous production of bovine Maedi-Visna-like viral antigens in Cf2Th cells |
| BR0113745A (pt) * | 2000-09-09 | 2004-03-02 | Akzo Nobel Nv | Vacina, teste diagnóstico e métodos para imunizar mamìferos e para preparar uma vacina |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3410839A (en) * | 1964-04-16 | 1968-11-12 | Rand Dev Corp | Immunochromatographic partition of soluble antigens |
-
1974
- 1974-01-23 US US435751A patent/US3873690A/en not_active Expired - Lifetime
- 1974-05-21 GB GB2252874A patent/GB1465345A/en not_active Expired
- 1974-05-28 DE DE19742425678 patent/DE2425678A1/de active Pending
- 1974-06-24 CA CA203,246A patent/CA1024890A/en not_active Expired
- 1974-10-22 JP JP49121082A patent/JPS50101523A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US3873690A (en) | 1975-03-25 |
| JPS50101523A (US06312121-20011106-C00033.png) | 1975-08-12 |
| CA1024890A (en) | 1978-01-24 |
| GB1465345A (en) | 1977-02-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3689717T2 (de) | Einen spezifischen Antikörper enthaltender Stoff aus Eiern, Verfahren zu dessen Herstellung und seine Anwendung. | |
| DE1810438A1 (de) | Prophylaktisches oder therapeutisches Praeparat | |
| DE2409862C3 (de) | Verwendung einer oral applizierbaren Immunoglobulinkombination | |
| DE3886999T2 (de) | Newcastle-krankheitsvirus-Impfstoff und Methode für seine Verwendung. | |
| DE3750225T2 (de) | Herstellung und verwendung von anti-helminthischen wirkstoffen und schutzantigenen. | |
| DE1951256C3 (de) | Verfahren zur Herstellung eines formalinisierten Allergens und dieses Allergen enthaltende Mitte! | |
| DE2403994A1 (de) | Herstellung von antisera | |
| DE2751454A1 (de) | Steuerung und umkehr der immunologischen alterung | |
| DE3783409T2 (de) | Verfahren zur besserung der qualitaet von tieren. | |
| DE1198489B (de) | Verfahren zur Herstellung eines Impfstoffes gegen Panleucopenie | |
| DE2425678A1 (de) | Verfahren zur herstellung eines impfstoffs gegen infektioese pferdeanaemie | |
| DE2639012C3 (de) | Inununtherapeutikum zur Prophylaxe und Therapie von Pseudomonas aeruginosa-Infektionen | |
| DE1767196A1 (de) | Loesliche Krebsantigene,die an Fremdproteine gebunden sind | |
| DE2854723C3 (de) | Hetero-Impfstoff zur therapeutischen Behandlung des Trichomonas -Syndroms und Verfahren zu seiner Herstellung | |
| DE3878982T2 (de) | Abgeschwaechtes virus und impfstoffe davon zur verwendung gegen infektionen bei gefluegel, verursacht durch truthahn-rhinotracheitis-virus. | |
| DE2620287A1 (de) | Verfahren zur wachstumsfoerderung von tieren | |
| DE2520310A1 (de) | Verfahren zur herstellung von immunisierender milch und/oder kolostrum | |
| DE2713680A1 (de) | Verfahren zur herstellung eines mittels mit mitogenen und/oder adjuvans-eigenschaften und dieses mittel enthaltende arzneimittel | |
| DE1617538C3 (de) | Verfahren zur Herstellung von Tetanus-Antitoxin | |
| DE2045160A1 (de) | Verfahren zur Herstellung einer Lebendvaccine gegen die infektiöse Bursitis der Huhner | |
| DE2034118A1 (en) | Xenogenic nucleic acids for enhancing antigenicity - of peptides and proteins | |
| DE2728806A1 (de) | Auf oralem wege einzunehmender antiparasitaerer impfstoff, verfahren zu dessen herstellung und anwendungsmethode des impfstoffs bei saeugetieren | |
| DE3235913C2 (de) | Verfahren zur Gewinnung eines Krankheitskontrollprodukts | |
| DE3877102T2 (de) | Methode fuer die behandlung von viraler gehirnentzuendung. | |
| DE2225548A1 (de) | Intravenoes vertraegliche staupe- und hepatitisvaccine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OHJ | Non-payment of the annual fee |